These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8682137)

  • 21. Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions.
    Ferguson JJ; Zaqqa M
    Drugs; 1999 Dec; 58(6):965-82. PubMed ID: 10651385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is heparin an acceptable anticoagulant when glycoprotein IIb/IIIa inhibitors are not used?
    Lee MS; Rha SW; Park KW; Kim MH
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):223-224. PubMed ID: 25616929
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists.
    Steinhubl SR
    Coron Artery Dis; 2003 Aug; 14(5):381-6. PubMed ID: 12878903
    [No Abstract]   [Full Text] [Related]  

  • 24. Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology.
    Tcheng JE
    Thromb Haemost; 1997 Jul; 78(1):205-9. PubMed ID: 9198154
    [No Abstract]   [Full Text] [Related]  

  • 25. [GPIIb/IIIa inhibitor].
    Ikeda Y
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1174-81. PubMed ID: 10771692
    [No Abstract]   [Full Text] [Related]  

  • 26. Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome.
    Li X; Cong H
    Tex Heart Inst J; 2009; 36(2):134-9. PubMed ID: 19436807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The platelet in acute coronary syndromes: defining the pivotal role of platelet glycoprotein IIb/IIIa receptor blockade.
    Jesse RL
    J Emerg Med; 1999; 17(3):575-80. PubMed ID: 10338259
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon.
    Dyke C; Bhatia D
    J Cardiovasc Surg (Torino); 1999 Aug; 40(4):505-16. PubMed ID: 10532207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis.
    Eccleston D; Topol EJ
    Coron Artery Dis; 1995 Dec; 6(12):947-55. PubMed ID: 8723017
    [No Abstract]   [Full Text] [Related]  

  • 31. Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes.
    Kandzari DE; Mahaffey KW
    J Interv Cardiol; 2002 Apr; 15(2):121-9. PubMed ID: 12063807
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in the pharmacology of acute coronary syndrome. Platelet inhibition.
    Tiffany BR; Barrali R
    Emerg Med Clin North Am; 2000 Nov; 18(4):723-43, vi. PubMed ID: 11130935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
    Vorchheimer DA; Fuster V
    Circulation; 1998 Feb; 97(4):312-4. PubMed ID: 9468202
    [No Abstract]   [Full Text] [Related]  

  • 34. [GP IIb/IIIa receptor antagonists--molecular and clinical aspects].
    Francuz T
    Postepy Hig Med Dosw; 2001; 55(3):419-32. PubMed ID: 11505641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lysis of an intracoronary thrombus with a glycoprotein IIb/IIIa antagonist].
    Ammann P; Naegeli B; Schuiki E; Bertel O
    Schweiz Med Wochenschr; 2000 Mar; 130(9):336. PubMed ID: 10746274
    [No Abstract]   [Full Text] [Related]  

  • 36. Glycoprotein IIb/IIIa inhibitors in unstable angina.
    Theroux P
    Curr Opin Cardiol; 1997 Sep; 12(5):447-52. PubMed ID: 9352171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade.
    Armstrong PW
    CMAJ; 1999 Nov; 161(11):1423-4. PubMed ID: 10906900
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
    Münzel TF; Post F
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S215-8. PubMed ID: 17109252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 40. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.